Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)
Most patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse prognosis. OYSTs are rare tumors and promising results are expected with the use of specif...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/2/220 |
| _version_ | 1797413964373557248 |
|---|---|
| author | Khalil Hodroj Aleksandra Stevovic Valery Attignon Domenico Ferraioli Pierre Meeus Sabrina Croce Nicolas Chopin Lea Rossi Anne Floquet Christine Rousset-Jablonski Olivier Tredan Frédéric Guyon Isabelle Treilleux Corinne Rannou Marie Morfouace Isabelle Ray-Coquard |
| author_facet | Khalil Hodroj Aleksandra Stevovic Valery Attignon Domenico Ferraioli Pierre Meeus Sabrina Croce Nicolas Chopin Lea Rossi Anne Floquet Christine Rousset-Jablonski Olivier Tredan Frédéric Guyon Isabelle Treilleux Corinne Rannou Marie Morfouace Isabelle Ray-Coquard |
| author_sort | Khalil Hodroj |
| collection | DOAJ |
| description | Most patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse prognosis. OYSTs are rare tumors and promising results are expected with the use of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens. We initiated a project in collaboration with EORTC SPECTA, to explore the molecular characteristics of OYSTs. The pilot project used retrospective samples from ten OYST relapsed and disease-free patients. Each patient had a molecular analysis performed with FoundationOne CDx describing the following variables according to the Foundation Medicine Incorporation (FMI): alteration type (SNV, deletion), actionable gene alteration, therapies approved in EU (for patient’s tumor type and other tumor types), tumor mutational burden (TMB), and microsatellite instability (MSI) status. A total of 10 patients with OYST diagnosed between 2007 and 2017 had a molecular analysis. A molecular alteration was identified in four patients (40%). A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in <i>KRAS</i>, <i>KIT</i>, <i>ARID1A</i>. Two patients at relapse harbored a targetable mutation. This retrospective study identifies clinically relevant molecular alterations for all relapsed patients with molecular analysis. Dedicated studies are needed to demonstrate the efficacy of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens and to explore the potential relationship of a molecular alteration and patient outcome. |
| first_indexed | 2024-03-09T05:26:03Z |
| format | Article |
| id | doaj.art-31c00cbc502247958b76b826c0ce2b6a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T05:26:03Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-31c00cbc502247958b76b826c0ce2b6a2023-12-03T12:36:30ZengMDPI AGCancers2072-66942021-01-0113222010.3390/cancers13020220Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)Khalil Hodroj0Aleksandra Stevovic1Valery Attignon2Domenico Ferraioli3Pierre Meeus4Sabrina Croce5Nicolas Chopin6Lea Rossi7Anne Floquet8Christine Rousset-Jablonski9Olivier Tredan10Frédéric Guyon11Isabelle Treilleux12Corinne Rannou13Marie Morfouace14Isabelle Ray-Coquard15Centre Léon Berard (CLB), 69008 Lyon, FranceEORTC, Translational Research, 1200 Brussels, BelgiumCentre Léon Berard (CLB), 69008 Lyon, FranceCentre Léon Berard (CLB), 69008 Lyon, FranceCentre Léon Berard (CLB), 69008 Lyon, FranceInstitut Bergonié, 33000 Bordeaux, FranceCentre Léon Berard (CLB), 69008 Lyon, FranceCentre Léon Berard (CLB), 69008 Lyon, FranceInstitut Bergonié, 33000 Bordeaux, FranceCentre Léon Berard (CLB), 69008 Lyon, FranceCentre Léon Berard (CLB), 69008 Lyon, FranceInstitut Bergonié, 33000 Bordeaux, FranceCentre Léon Berard (CLB), 69008 Lyon, FranceCentre Léon Berard (CLB), 69008 Lyon, FranceEORTC, Translational Research, 1200 Brussels, BelgiumCentre Léon Berard (CLB), 69008 Lyon, FranceMost patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse prognosis. OYSTs are rare tumors and promising results are expected with the use of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens. We initiated a project in collaboration with EORTC SPECTA, to explore the molecular characteristics of OYSTs. The pilot project used retrospective samples from ten OYST relapsed and disease-free patients. Each patient had a molecular analysis performed with FoundationOne CDx describing the following variables according to the Foundation Medicine Incorporation (FMI): alteration type (SNV, deletion), actionable gene alteration, therapies approved in EU (for patient’s tumor type and other tumor types), tumor mutational burden (TMB), and microsatellite instability (MSI) status. A total of 10 patients with OYST diagnosed between 2007 and 2017 had a molecular analysis. A molecular alteration was identified in four patients (40%). A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in <i>KRAS</i>, <i>KIT</i>, <i>ARID1A</i>. Two patients at relapse harbored a targetable mutation. This retrospective study identifies clinically relevant molecular alterations for all relapsed patients with molecular analysis. Dedicated studies are needed to demonstrate the efficacy of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens and to explore the potential relationship of a molecular alteration and patient outcome.https://www.mdpi.com/2072-6694/13/2/220OYSTmolecular characteristicstargetable mutationpatient outcome |
| spellingShingle | Khalil Hodroj Aleksandra Stevovic Valery Attignon Domenico Ferraioli Pierre Meeus Sabrina Croce Nicolas Chopin Lea Rossi Anne Floquet Christine Rousset-Jablonski Olivier Tredan Frédéric Guyon Isabelle Treilleux Corinne Rannou Marie Morfouace Isabelle Ray-Coquard Molecular Characterization of Ovarian Yolk Sac Tumor (OYST) Cancers OYST molecular characteristics targetable mutation patient outcome |
| title | Molecular Characterization of Ovarian Yolk Sac Tumor (OYST) |
| title_full | Molecular Characterization of Ovarian Yolk Sac Tumor (OYST) |
| title_fullStr | Molecular Characterization of Ovarian Yolk Sac Tumor (OYST) |
| title_full_unstemmed | Molecular Characterization of Ovarian Yolk Sac Tumor (OYST) |
| title_short | Molecular Characterization of Ovarian Yolk Sac Tumor (OYST) |
| title_sort | molecular characterization of ovarian yolk sac tumor oyst |
| topic | OYST molecular characteristics targetable mutation patient outcome |
| url | https://www.mdpi.com/2072-6694/13/2/220 |
| work_keys_str_mv | AT khalilhodroj molecularcharacterizationofovarianyolksactumoroyst AT aleksandrastevovic molecularcharacterizationofovarianyolksactumoroyst AT valeryattignon molecularcharacterizationofovarianyolksactumoroyst AT domenicoferraioli molecularcharacterizationofovarianyolksactumoroyst AT pierremeeus molecularcharacterizationofovarianyolksactumoroyst AT sabrinacroce molecularcharacterizationofovarianyolksactumoroyst AT nicolaschopin molecularcharacterizationofovarianyolksactumoroyst AT learossi molecularcharacterizationofovarianyolksactumoroyst AT annefloquet molecularcharacterizationofovarianyolksactumoroyst AT christineroussetjablonski molecularcharacterizationofovarianyolksactumoroyst AT oliviertredan molecularcharacterizationofovarianyolksactumoroyst AT fredericguyon molecularcharacterizationofovarianyolksactumoroyst AT isabelletreilleux molecularcharacterizationofovarianyolksactumoroyst AT corinnerannou molecularcharacterizationofovarianyolksactumoroyst AT mariemorfouace molecularcharacterizationofovarianyolksactumoroyst AT isabelleraycoquard molecularcharacterizationofovarianyolksactumoroyst |